Table 1.

Clinical trials with novel intralesional agents

Trial no.	Agent	Sponsor	Phase	Indication	References
N/A	OncoVEXGM−CSF	Biovex	I	Breast, gastrointestinal adenocarcinoma, malignant melanoma, HNSCC	[37]
NCT00289016	OncoVEXGM−CSF	Biovex	II	Stage IIIC and IV melanoma	[38]
NCT00769704	Talimogene laherparepvec	Amgen	III	Unresected stage IIIB/C and IV melanoma	[8]
NCT01740297	T-Vec + Ipilimumab	Amgen	Ib/II	Unresected stage IIIB/C and IV melanoma	[42]
NCT02263508	T-Vec + Pembrolizumab	Amgen, MSD	III	Unresectable stage IIIB to IVM1c melanoma	[43]
NCT02211131	T-Vec	Amgen	II	Resectable stage IIIB/C and IVM1a melanoma (neoadjuvant)	N/A
NCT00219843	PV-10 (rose bengal)	Provectus	I	Stage III and IV metastatic melanoma	[45]
NCT00521053	PV-10 (rose bengal)	Provectus	II	Stage III and IV metastatic melanoma	[47]
NCT02288897	PV-10 (rose bengal)	Provectus	III	Stage IIIB, IIIC or Stage IV M1a with no active nodal metastases	N/A
NCT01253096	Darleukin (L19IL2)	Philogen	II	Stage IIIB/C melanoma	[15]
NCT02076633	Daromun (L19IL2 + L19TNF)	Philogen	II	Stage IIIB/C and IVM1a melanoma	[56]
NCT02938299	Daromun (L19IL2 + L19TNF)	Philogen	III	Resectable stage IIIB/C melanoma (neoadjuvant)	N/A

N/A not applicable